Literature DB >> 21777618

The complexity of Sjögren's syndrome: novel aspects on pathogenesis.

Roland Jonsson1, Petra Vogelsang, Roman Volchenkov, Alexander Espinosa, Marie Wahren-Herlenius, Silke Appel.   

Abstract

In Sjögren's syndrome, like in most other autoimmune diseases, the enigma leading to a pathogenic attack against self has not yet been solved. By definition, the disease must be mediated by specific immune reactions against endogenous tissues to qualify as an autoimmune disease. In Sjögren's syndrome the autoimmune response is directed against the exocrine glands, which, as histopathological hallmark of the disease, display persistent and progressive focal mononuclear cell infiltrates. Clinically, the disease in most patients is manifested by two severe symptoms: dryness of the mouth (xerostomia) and the eyes (keratoconjunctivitis sicca). A number of systemic features have also been described and the presence of autoantibodies against the ubiquitously expressed ribonucleoprotein particles Ro (Sjögren's-syndrome-related antigen A - SSA) and La (SSB) further underline the systemic nature of Sjögren's syndrome. The original explanatory concept for the pathogenesis of Sjögren's syndrome proposed a specific, self-perpetuating, immune mediated loss of acinar and ductal cells as the principal cause of salivary gland hypofunction. Although straightforward and plausible, the hypothesis, however, falls short of accommodating several Sjögren's syndrome-related phenomena and experimental findings. Consequently, researchers considered immune-mediated salivary gland dysfunction prior to glandular destruction and atrophy as potential molecular mechanisms underlying the symptoms of dryness in Sjögren's syndrome. Accordingly, apoptosis, fibrosis and atrophy of the salivary glands would represent consequences of salivary gland hypofunction. The emergence of advanced bio-analytical platforms further enabled the identification of potential biomarkers with the intent to improve Sjögren's syndrome diagnosis, promote the development of prognostic tools for Sjögren's syndrome and the long-term goal to identify possible processes for therapeutic treatment interventions. In addition, such approaches allowed us to glimpse at the apparent complexity of Sjögren's syndrome. Copyright Â
© 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21777618     DOI: 10.1016/j.imlet.2011.06.007

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  61 in total

1.  Upregulation of long noncoding RNA TMEVPG1 enhances T helper type 1 cell response in patients with Sjögren syndrome.

Authors:  Juan Wang; Huiyong Peng; Jie Tian; Jie Ma; Xinyi Tang; Ke Rui; Xinyu Tian; Yungang Wang; Jianguo Chen; Liwei Lu; Huaxi Xu; Shengjun Wang
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

2.  A possible genetic association with chronic fatigue in primary Sjögren's syndrome: a candidate gene study.

Authors:  Katrine Brække Norheim; Stephanie Le Hellard; Gunnel Nordmark; Erna Harboe; Lasse Gøransson; Johan G Brun; Marie Wahren-Herlenius; Roland Jonsson; Roald Omdal
Journal:  Rheumatol Int       Date:  2013-09-03       Impact factor: 2.631

3.  Single-cell analysis of glandular T cell receptors in Sjögren's syndrome.

Authors:  Michelle L Joachims; Kerry M Leehan; Christina Lawrence; Richard C Pelikan; Jacen S Moore; Zijian Pan; Astrid Rasmussen; Lida Radfar; David M Lewis; Kiely M Grundahl; Jennifer A Kelly; Graham B Wiley; Mikhail Shugay; Dmitriy M Chudakov; Christopher J Lessard; Donald U Stone; R Hal Scofield; Courtney G Montgomery; Kathy L Sivils; Linda F Thompson; A Darise Farris
Journal:  JCI Insight       Date:  2016-06-02

4.  Suppression of age-related salivary gland autoimmunity by glycosylation-dependent galectin-1-driven immune inhibitory circuits.

Authors:  Verónica C Martínez Allo; Vanesa Hauk; Nicolas Sarbia; Nicolás A Pinto; Diego O Croci; Tomás Dalotto-Moreno; Rosa M Morales; Sabrina G Gatto; Montana N Manselle Cocco; Juan C Stupirski; Ángel Deladoey; Esteban Maronna; Priscila Marcaida; Virginia Durigan; Anastasia Secco; Marta Mamani; Alicia Dos Santos; Antonio Catalán Pellet; Claudia Pérez Leiros; Gabriel A Rabinovich; Marta A Toscano
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-11       Impact factor: 11.205

Review 5.  Th17 cells in autoimmune diseases.

Authors:  Lei Han; Jing Yang; Xiuwen Wang; Dan Li; Ling Lv; Bin Li
Journal:  Front Med       Date:  2015-02-04       Impact factor: 4.592

6.  Bilateral Internuclear Ophthalmoplegia as a Presenting Manifestation of Primary Sjögren's Syndrome.

Authors:  K S Natsis; E Boura; O Kyriazis; A Iliadis; S-A Syntila; I Kostopoulos; T Afrantou
Journal:  Neuroophthalmology       Date:  2016-09-07

7.  Minor salivary gland fibrosis in Sjögren's syndrome is elevated, associated with focus score and not solely a consequence of aging.

Authors:  Kerry M Leehan; Nathan P Pezant; Astrid Rasmussen; Kiely Grundahl; Jacen S Moore; Lida Radfar; David M Lewis; Donald U Stone; Christopher J Lessard; Nelson L Rhodus; Barbara M Segal; R Hal Scofield; Kathy L Sivils; Courtney Montgomery; A Darise Farris
Journal:  Clin Exp Rheumatol       Date:  2017-10-23       Impact factor: 4.473

8.  Activation of plasmacytoid dendritic cells by apoptotic particles - mechanism for the loss of immunological tolerance in Sjögren's syndrome.

Authors:  M Ainola; P Porola; Y Takakubo; B Przybyla; V P Kouri; T A Tolvanen; A Hänninen; D C Nordström
Journal:  Clin Exp Immunol       Date:  2017-11-28       Impact factor: 4.330

9.  Manifestation of meibomian gland dysfunction in patients with Sjögren's syndrome, non-Sjögren's dry eye, and non-dry eye controls.

Authors:  Yeon Soo Kang; Hyo Seok Lee; Ying Li; Won Choi; Kyung Chul Yoon
Journal:  Int Ophthalmol       Date:  2017-05-31       Impact factor: 2.031

10.  Muscarinic type 3 receptor autoantibodies are associated with anti-SSA/Ro autoantibodies in Sjögren's syndrome.

Authors:  Jian Zuo; Adrienne E G Williams; Yun-Jong Park; Kevin Choi; Annie L Chan; Westley H Reeves; Michael R Bubb; Yun Jong Lee; Kyungpyo Park; Carol M Stewart; Seunghee Cha
Journal:  J Immunol Methods       Date:  2016-07-25       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.